Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB05465> ?p ?o ?g. }
Showing items 1 to 15 of
15
with 100 items per page.
- drugbank:DB05465 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05465 label "MLN-518 [drugbank:DB05465]" assertion.
- drugbank:DB05465 seeAlso DB05465 assertion.
- drugbank:DB05465 identifier "drugbank:DB05465" assertion.
- drugbank:DB05465 description "MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations. Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway." assertion.
- drugbank:DB05465 title "MLN-518" assertion.
- drugbank:DB05465 bio2rdf_vocabulary:identifier "DB05465" assertion.
- drugbank:DB05465 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05465 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05465" assertion.
- drugbank:DB05465 bio2rdf_vocabulary:x-identifiers.org DB05465 assertion.
- drugbank:DB05465 drugbank_vocabulary:drugbank-id "DB05465" assertion.
- drugbank:DB05465 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05465 drugbank_vocabulary:x-chemspider chemspider:2302085 assertion.
- drugbank:DB05465 drugbank_vocabulary:x-pubchemcompound pubchem.compound:3038522 assertion.
- drugbank:DB05465 drugbank_vocabulary:x-bindingdb bindingdb:13535 assertion.